The past quarter has been of great progress in AMYPAD, and major milestones were achieved for the Prognostic and Natural History Study (PNHS). After the great news of the first recruitment in Amsterdam at the VU medisch centrum (VUmc, the Netherlands) in October 2018, three more sites received approvals and were activated:
-
Barcelonaβeta Brain Research Center, BBRC (Barcelona, Spain)
-
University of Edinburgh, UEDIN (Edinburgh, UK)
-
CHU de Toulouse, CHUT (Toulouse, France).
Four sites are now actively enrolling participants in the AMYPAD PNHS across four European countries. The PNHS team has already contacted 126 participants of which 55 have already consented. The University of Geneva (UNIGE, Switzerland) has received all approvals and will be activated in the coming days. Other wave 1 sites are all lined up for approvals and the expectation is that these main wave 1 sites will all be actively recruiting before the end of the second quarter in 2019. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.
